Kansas City Research Institute Introduces Non-Invasive Technology
for Liver Disease Diagnosis


Non-invasive examination replaces costly, painful biopsy procedure


December 17, 2013 (Kansas City, Mo.) – The Kansas City Research Institute (KCRI) today introduced to the region a new medical technology that eliminates invasive procedures from liver disease diagnosis. The painless, non-invasive liver scan is performed using transient elastography to assess liver stiffness, and the cost for procedure is less than current examination methods.


The technology, called FibroScan, is used in the clinical management of patients with liver disease such as chronic viral hepatitis C and B and fatty liver diseases. The first clinically validated device using transient elastography, FibroScan measures liver shear wave speed and equivalent stiffness in a quick, non-invasive and painless procedure, according to Echosens, the manufacturer of FibroScan.


“In comparison to the costlier alternative of a liver biopsy which can take several hours to complete, FibroScan is a 10-minute process that completely changes the way we conduct this procedure,” said Bradley L. Freilich, MD, AGAF, Medical Director of The Liver and Pancreas Institute of Kansas City at Research Medical Center and Kansas City Research Institute.


The procedure is a less expensive alternative for identifying liver fibrosis or scar tissue. Determination of liver damage is important to help prevent complications such as liver failure and liver cancer, as well as an incentive to reverse the cause of the damage.


FibroScan will be used as a cutting-edge tool at the new Hepatitis Treatment Clinic (HTC) within KCRI. HTC, located at Research Medical Center’s Brookside Campus, will provide care to patients with any form of chronic inflammation of the liver.


FibroScan was first introduced in Europe in 2003 and received clearance by the US Food and Drug Administration (FDA) in April 2013. This year, The Centers for Disease Control and Prevention also recommended that Americans born between 1945 and 1965 be tested for hepatitis C, as these individuals are more susceptible to the disease.



About Kansas City Research Institute

Kansas City Research Institute conducts clinical trials yielding results that empower medical professionals and patients to make informed health care decisions by advancing medical knowledge, promoting new and promising treatments, and facilitating access to otherwise unobtainable medications. For more information, please visit www.kcresearchinstitute.com.